Skip to main
TDOC

Teladoc (TDOC) Stock Forecast & Price Target

Teladoc (TDOC) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 17%
Buy 11%
Hold 72%
Sell 0%
Strong Sell 0%

Bulls say

Teladoc Health Inc. is projecting robust growth in its Integrated Care and BetterHelp segments, with forecasted Integrated Care revenue reaching $1.6136 billion in CY26, reflecting an annual increase of $34 million. The company anticipates a significant rise in insurance revenue for BetterHelp, estimating it will expand from $13 million in CY25 to between $75 million and $90 million in CY26, thus increasing its share of the revenue mix from 1.4% to 9%. Additionally, the Integrated Care segment's adjusted EBITDA is expected to rise to $251.9 million in CY26, demonstrating a year-over-year growth of $12.6 million and highlighting the anticipated strength of the EBITDA margin in the fourth quarter.

Bears say

Teladoc Health's outlook is negatively impacted by anticipated declines in the BetterHelp segment, which is expected to face a $40.5 million adjusted EBITDA headwind in CY26, resulting from a forecasted reduction in membership and low-single-digit growth targets over the next three years. Additionally, the company's revenue growth slowdown, particularly from BetterHelp, has led to a decrease in its valuation multiple, which currently sits well below its long-term average, reflecting heightened financial uncertainty. Furthermore, the shift from fee-based revenue to visit-based structures in the Integrated Care segment, coupled with expected declines in health plan enrollments due to expiring ACA subsidies, may exacerbate revenue fluctuations and hinder overall growth potential.

Teladoc (TDOC) has been analyzed by 18 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 11% recommend Buy, 72% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teladoc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teladoc (TDOC) Forecast

Analysts have given Teladoc (TDOC) a Hold based on their latest research and market trends.

According to 18 analysts, Teladoc (TDOC) has a Hold consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.61, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.61, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teladoc (TDOC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.